NavDx®
Order Guide

NavDx®

Optimizing HPV+ Cancer Care

How to order

NAVERIS PROVIDER PORTAL

An ordering experience that respects your time

Streamlined ordering process
Complete, sign and submit test orders from our secure provider portal

Realtime access to order status, test results and patients' testing histories
Review order status, receive and download test results, and view testing histories for your patients

Automate serial testing during surveillance
The MRD Surveillance Notification Program enables you to receive a patient's Test Requisition Forms (TRFs) during surveillance, based on your specified intervals.

Always be prepared — order NavDx Test Kits for your practice

DOCTOR OFFICE BLOOD COLLECTION

If you're seeing a patient and would like to draw blood on-site:

1. Place order on the Provider Portal and print a copy of the signed Test Requisition Form, to return with patient's sample
2. Apply the included patient label to the collection tube and complete the blood draw
3. Enclose sample and the printed Test Requisition Form in the NavDx test kit and submit via FedEx

OFFSITE BLOOD COLLECTION

For ulitmate patient convenience, use our Mobile or Walk-in Clinic Phlebotomy Service for convenient blood collections:

1. Place order on the Provider Portal and select *Mobile/Offsite Phlebotomy Service*
2. Provide a target blood draw date and indicate whether a test kit was provided to the patient by your office

Ordering providers will receive a NavDx Patient Report within 7 days from the date the Naveris lab receives the sample.

Sample requirements



- **Test sample:** One 10 mL tube of whole blood. Minimum sample required is 8 mL whole blood.
- **Storage and shipping:** Do not freeze or refrigerate. Ship same or next day at room temperature.

Note: NavDx® testing can be performed on diagnostic tumor tissue to confirm HPV status. Preferred sample is five, 5-µm formalin-fixed, paraffin-embedded sections, as curls or on unstained slides. Alternatively, a tissue block can be submitted and will be returned.

Testing Schedule

Clinical practice guidelines and CMS coverage policy for recurrence detection include surveillance at specified intervals:

During Surveillance

- **≤2 years post treatment:** every 3 months
- **3-5 years post treatment:** every 6 months
- **6+ years post treatment:** 1 time per year

Pretreatment

Use the NavDx test at least 7 days after any biopsy procedure, and prior to initiating treatment

During Treatment

Consider NavDx testing to assess early response to treatment

NavDx®
Optimizing HPV+ Cancer Care

In HPV-driven OPSCC Surveillance

Let their blood TTMV® Score help achieve a new standard of care

The NavDx test is the first and only clinically validated circulating tumor tissue modified viral (TTMV)-HPV DNA blood test that aids in the detection of HPV-driven cancer.[1] Monitoring TTMV-HPV DNA Scores with the NavDx test at routine surveillance visits has demonstrated unrivaled test performance metrics, assuring earlier detection of patients with residual/recurrent disease.[2-4]

- Distinguish TTMV-HPV DNA from non-cancerous sources of HPV DNA[5]
- **≥97% Specificity** and **≥89% Sensitivity** to more accurately detect true disease status[2,3]
- **≥98% NPV** with no recurrence when TTMV-HPV DNA remained undetectable[2,3]
- **≥95% PPV** for cancer recurrence, when patients had 1 positive test result[2,3]
- **Accurately detect recurrence a median of 4 months earlier** than it would present clinically via PET or CT scan to facilitate earlier initiation of salvage therapy[1]

If you have questions or would like additional information, contact us at **support@naveris.com**, **(833) 628-3747 or visit navdx.com**

References: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. *J Clin Oncol*. 2020;38(10):1050-1058. **2.** Ferrandino RN, Chen S, Kappauf C, et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus–associated oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. doi: 10.1001 /jamaoto.2023.1937. **3.** Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res 2023. doi: 10.1158/ 1078-0432. CCR -23-1478. **4.** Berger BM, Hanna GJ et al; Clin Cancer Res 2022;28(19):4292–4301. **5**. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. *Clin Cancer Res*. 2019;25(15):4682-4690.

NAVERIS®

Naveris Inc., 21 Hickory Drive, Suite 600, Waltham, MA 02451, www.narveris.com | contact@naveris.com

NavDx®

Optimizing HPV+ Cancer Care